SAINT HELIER (dpa-AFX) - Sangamo BioSciences, Inc. (SGMO) announced that it entered into a collaboration and license agreement with Shire plc (SHP.L, SHPGY) to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein, or ZFP, technology. Shire will receive exclusive world-wide rights to ZFP Therapeutics designed to target four genes, which will be used to investigate curative therapies for hemophilia A and B. Shire also receives the right to designate three additional gene targets. Sangamo is responsible for all activities through submission of Investigational New Drug Applications and European Clinical Trial Applications for each product and Shire will reimburse Sangamo for its internal and external research program-related costs. Shire is responsible for clinical development and commercialization of products arising from the alliance. Shire will pay Sangamo $13 million upfront followed by research, regulatory, development and commercial milestone payments, and royalties on product sales.
Copyright RTT News/dpa-AFX
© 2012 AFX News
